Immunic (IMUX) Operating Expenses (2013 - 2026)

Immunic (IMUX) has 14 years of Operating Expenses data on file, last reported at $33.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 23.9% year-over-year to $33.2 million; the trailing twelve-month figure through Mar 2026 stood at $109.6 million (up 8.56% YoY), and the FY2025 full-year result was $103.2 million, up 5.28% from the prior year.
• Operating Expenses grew to $33.2 million in Q1 2026, from $23.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $57.3 million in Q4 2022 to a low of $20.1 million in Q3 2022.
• A 5-year average of $26.7 million and a median of $25.0 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 163.92% in 2022 and tumbled 59.21% in 2023, its largest moves.
• Tracing IMUX's Operating Expenses over 5 years: stood at $57.3 million in 2022, then plunged by 59.21% to $23.4 million in 2023, then climbed by 9.62% to $25.6 million in 2024, then slipped by 8.99% to $23.3 million in 2025, then jumped by 42.47% to $33.2 million in 2026.
• Business Quant data shows IMUX's Operating Expenses at $33.2 million in Q1 2026, $23.3 million in Q4 2025, and $26.0 million in Q3 2025.